Uningwei (301166) 2023 Annual Report Review and 2024 Quarterly Report Review: Short-term performance is pressured by product line continues to expand

Incident: The company announced its 2023 annual report. In 2023, it achieved revenue of 1,226 billion yuan, an increase of 2.57% over the previous year; realized net profit of 40 million yuan, a year-on-year decrease of 62.18%. Company Announcements 202

西部證券Apr 29 15:41

Uningwei (301166.SZ): Net profit of 5.202,500 yuan in the first quarter decreased by 70.97% year on year

On April 26, Ge Longhui (301166.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 272 million yuan, down 0.91% year on year; net profit attributable to shareholders of listed companies was 5.202,500 yuan, down 70.97% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 357,500 yuan, down 96.66% year on year; basic earnings per share were 0.06 yuan.

Gelonghui FinanceApr 26 16:04

Unionway (301166.SZ): By the end of 2023, the number of SKUs in the company had exceeded 9 million

On April 24, Gelonghui (301166.SZ) said on the investor interactive platform that by the end of 2023, the number of SKUs in the company had exceeded 9 million. The biological reagent products currently provided by the company are mainly aimed at customers in the field of scientific research. This type of customer has high requirements for product quality and stability. Currently, these biological reagents are still mainly foreign brands. With the booming development of life science, China's own brands of life science-related reagents are gradually becoming cost-effective and of high quality. As the company continues to expand its product pipeline, some domestic brands have also been incorporated into the company's product system, and at the same time passed

Gelonghui FinanceApr 24 15:26

Uningwei (301166.SZ): Customers are mainly domestic institutions of higher learning, research institutes, hospitals and biomedical companies

Gelonghui, April 24 | Uningwei (301166.SZ) said on the investor interactive platform that the company's customers are mainly domestic institutions of higher learning, research institutes, hospitals and biomedical companies. Among them, biomedical companies are important customers of the company and have cooperated with Hengrui Pharmaceutical, Shanghai Pharmaceutical, and Wantai Biotech. At present, the company has covered more than 50 domestic and foreign biomedical companies and related listed companies, and provided them with life science reagents, equipment, consumables and laboratory services in the field of scientific research.

Gelonghui FinanceApr 24 15:24

Uningwei (301166.SZ): 2023 net profit of 403.18,800 yuan, plan to distribute 10 to 4.7 yuan

On April 22, Ge Longhui (301166.SZ) announced its 2023 annual report, with operating income of 1,226 billion yuan, up 2.57% year on year; net profit attributable to shareholders of listed companies was 403.18,800 yuan, down 62.18% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 12.2941 million yuan, down 85.59% year on year; basic income per share was 0.47 yuan; it plans to distribute a cash dividend of 4.7 yuan (tax included) for every 10 shares to all shareholders.

Gelonghui FinanceApr 22 17:04

Uningwei (301166.SZ): Peger Biotech and Jiuyuan Gene are both company customers

Gelonghui, April 9 | Uningwei (301166.SZ) said on the investor interactive platform that the company mainly provides domestic customers with life science reagents, equipment, consumables and laboratory services in the field of scientific research for customers such as universities, research institutes, hospitals and biomedical companies. Peger Biotech and Jiuyuan Gene are both company customers.

Gelonghui FinanceApr 9 17:33